Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.58 |
| ▸ | GABRA5 | P31644 | 11/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.53 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2925549 | 0.86 | ALDH1A1 (0.48) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL1777617 | 0.84 | GABRA5 (0.46) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL256699 | 0.84 | PTGS1 (0.59) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL2929690 | 0.83 | GABRA5 (0.49) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL2928713 | 0.83 | GABRA5 (0.52) | GABRA5 | |
| SCHEMBL22230645 | 0.83 | GABRA5 (0.49) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL286403 | 0.83 | GABRA5 (0.52) | PTGS1PTGS2GABRA5KMT2A | |
| SCHEMBL2924159 | 0.82 | GABRA5 (0.54) | GABRA5ALDH1A1NPSR1MEN1GAA | |
| SCHEMBL286436 | 0.82 | PTGS1 (0.58) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 | |
| SCHEMBL935024 | 0.82 | PTGS1 (0.58) | PTGS1PTGS2GABRA5ALDH1A1NPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 86 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2427456-B1 | ISOXAZOLE-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2020-02-05 | — | — | EP | disclosed |
| EP-2231651-B1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2018-11-21 | — | — | EP | disclosed |
| EP-2229383-B1 | ISOXAZOLO-PYRAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2768827-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-11-23 | — | — | EP | disclosed |
| EP-2768827-B1 | PROCESS FOR THE PREPARATION OF ISOXAZOLYL-METHOXY-NICOTINIC ACIDS | HOFFMANN LA ROCHE (CH) | 2016-11-23 | — | — | EP | disclosed |
| EP-2427459-B1 | ISOXAZOLE-THIAZOLE DERIVATIVES AS GABA A RECEPTOR INVERSE AGONISTS FOR USE IN THE TREATMENT OF COGNITIVE DISORDERS | HOFFMANN LA ROCHE (CH) | 2016-09-28 | — | — | EP | disclosed |
| EP-2767536-B1 | Isoxazolo-pyridine derivatives | HOFFMANN LA ROCHE (CH) | 2015-09-02 | — | — | EP | disclosed |
| US-9073908-B2 | Isoxazolo-pyridine derivatives | ROCHE PALO ALTO LLC (US) | 2015-07-07 | — | — | US | disclosed |
| EP-2227467-B1 | ISOXAZOLO-PYRIDINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2014-12-31 | — | — | EP | disclosed |
| CN-102414205-B | Isoxazole-pyrazole derivatives | HOFFMANN LA ROCHE | 2014-11-05 | — | — | CN | disclosed |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | ROCHE PALO ALTO LLC | 2009-06-04 | — | — | US | disclosed |
| CN-101325874-A | Trioxane dimers having high anticancer and long-lasting antimalarial activities | UNIV JOHNS HOPKINS (US) | 2008-12-17 | — | — | CN | disclosed |
| EP-1343775-B1 | PIPERAZINE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2008-06-04 | — | — | EP | disclosed |
| WO-2007067333-A2 | TRIOXANE DIMERS HAVING HIGH ANTICANCER AND LONG-LASTING ANTIMALARIAL ACTIVITIES | JOHNS HOPKINS UNIVERSITY (US) | 2007-06-14 | — | — | WO | disclosed |
| US-7022707-B2 | Piperazine derivatives | HOFFMAN-LA ROCHE INC. (US) | 2006-04-04 | — | — | US | disclosed |
| US-20040235859-A1 | Novel piperazine derivatives | ADAMS DAVID REGINALD (GB) | 2004-11-25 | — | — | US | disclosed |
| EP-1343775-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2003-09-17 | — | — | EP | disclosed |
| US-20020143020-A1 | Novel piperazine derivatives | VERNALIS RESEARCH LIMITED (GB) | 2002-10-03 | — | — | US | disclosed |
| WO-2002048124-A2 | PIPERAZINE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2002-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143371-A1 | ISOXAZOLE-PYRIDINE DERIVATIVES | GABRA5, GABRA1, CHRNA5 | PTGS1 2443/4885PTGS2 3620/4885GABRA5 1/4885 |
| US-20090143385-A1 | ISOXAZOLO-PYRIDAZINE DERIVATIVES | GABRA5, CHRNA5, GABRA1 | PTGS1 1233/4885PTGS2 1436/4885GABRA5 1/4885 |
| US-20020143020-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | PTGS1 659/4885PTGS2 2148/4885GABRA5 1144/4885 |
| US-20040235859-A1 | Novel piperazine derivatives | CYP4B1, UGT1A1, CYP1B1 | PTGS1 659/4885PTGS2 2148/4885GABRA5 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.